Lea Sarov-Blat
Overview
Explore the profile of Lea Sarov-Blat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abedini A, Levinsohn J, Klotzer K, Dumoulin B, Ma Z, Frederick J, et al.
Nat Genet
. 2024 Jul;
56(8):1712-1724.
PMID: 39048792
Kidneys are intricate three-dimensional structures in the body, yet the spatial and molecular principles of kidney health and disease remain inadequately understood. We generated high-quality datasets for 81 samples, including...
2.
Cheriyan J, Roberts A, Roberts C, Graves M, Patterson I, Slough R, et al.
J Magn Reson Imaging
. 2022 Mar;
56(2):450-461.
PMID: 35343008
Background: Methods for accurate quantification of lung fluid in heart failure (HF) are needed. Dynamic contrast-enhanced (DCE)-MRI may be an appropriate modality. Purpose: DCE-MRI evaluation of fraction of fluid volume...
3.
Townsend R, Guarnieri P, Argyropoulos C, Blady S, Boustany-Kari C, Devalaraja-Narashimha K, et al.
Kidney Int
. 2020 Jan;
97(1):10-13.
PMID: 31901339
No abstract available.
4.
Waterworth D, Li L, Scott R, Warren L, Gillson C, Aponte J, et al.
J Am Heart Assoc
. 2014 Aug;
3(4).
PMID: 25164947
Background: Genetics can be used to predict drug effects and generate hypotheses around alternative indications. To support Losmapimod, a p38 mitogen-activated protein kinase inhibitor in development for acute coronary syndrome,...
5.
Newby L, Marber M, Melloni C, Sarov-Blat L, Aberle L, Aylward P, et al.
Lancet
. 2014 Jun;
384(9949):1187-95.
PMID: 24930728
Background: p38 MAPK inhibition has potential myocardial protective effects. We assessed losmapimod, a potent oral p38 MAPK inhibitor, in patients with non-ST-segment elevation myocardial infarction (NSTEMI) in a double-blind, randomised,...
6.
Tawakol A, Singh P, Rudd J, Soffer J, Cai G, Vucic E, et al.
J Am Coll Cardiol
. 2013 Aug;
63(1):86-8.
PMID: 23973698
No abstract available.
7.
Barbour A, Sarov-Blat L, Cai G, Fossler M, Sprecher D, Graggaber J, et al.
Br J Clin Pharmacol
. 2012 Dec;
76(1):99-106.
PMID: 23215699
Aims: The purpose of this study was to establish safety and tolerability of a single intravenous (IV) infusion of a p38 mitogen-activated protein kinase inhibitor, losmapimod, to obtain therapeutic levels...
8.
Melloni C, Sprecher D, Sarov-Blat L, Patel M, Heitner J, Hamm C, et al.
Am Heart J
. 2012 Nov;
164(5):646-653.e3.
PMID: 23137494
The p38 mitogen-activated protein kinase (MAPK) is a nexus point in inflammation, sensing, and stimulating cytokine production and driving cell migration and death. In acute coronary syndromes, p38MAPK inhibition could...
9.
Elkhawad M, Rudd J, Sarov-Blat L, Cai G, Wells R, Davies L, et al.
JACC Cardiovasc Imaging
. 2012 Sep;
5(9):911-22.
PMID: 22974804
Objectives: This study sought to determine the effects of a p38 mitogen-activated protein kinase inhibitor, losmapimod, on vascular inflammation, by (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography imaging. Background: The p38...
10.
Cheriyan J, Webb A, Sarov-Blat L, Elkhawad M, Wallace S, Maki-Petaja K, et al.
Circulation
. 2011 Jan;
123(5):515-23.
PMID: 21262998
Background: Oxidized low-density lipoprotein reduces endothelial nitric oxide production (an important mediator of vasoregulation) and activates p38 mitogen-activated protein kinase (MAPK), a mediator of vascular inflammation. Animal models of vascular...